Search company, investor...

Aliva Biopharmaceuticals

Stage

Grant | Alive

Total Raised

$100K

Last Raised

$100K | 15 yrs ago

About Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Headquarters Location

11 West Del Mar Boulevard,

Pasadena, California, 91105,

United States

626-683-9812

Missing: Aliva Biopharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aliva Biopharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Aliva Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aliva Biopharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Aliva Biopharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Aliva Biopharmaceuticals's headquarters?

    Aliva Biopharmaceuticals's headquarters is located at 11 West Del Mar Boulevard,, Pasadena.

  • What is Aliva Biopharmaceuticals's latest funding round?

    Aliva Biopharmaceuticals's latest funding round is Grant.

  • How much did Aliva Biopharmaceuticals raise?

    Aliva Biopharmaceuticals raised a total of $100K.

  • Who are the investors of Aliva Biopharmaceuticals?

    Investors of Aliva Biopharmaceuticals include National Science Foundation and California Technology Ventures.

  • Who are Aliva Biopharmaceuticals's competitors?

    Competitors of Aliva Biopharmaceuticals include Oligomerix, Apitope, Clinipace, Noveome Biotherapeutics, Hawaii Biotech, Dendreon, Open Monoclonal Technology, Cebix, Versartis, Calibrant Biosystems and 22 more.

Compare Aliva Biopharmaceuticals to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

B
Biosceptre International

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

B
BioPro Pharmaceutical

BioPro Pharmaceutical is the first regional biotech company in Asia to develop, market leading biopharmaceutical medicines, as well as many of the world's best known biopharmaceutical products. BioPro Pharmaceutical , Inc. has infrastructure in place in all major countries in Asia to target the market of US$30 billion. BioPro's expertise is in providing creative pharmaceutical solutions to small and medium-sized US or European companies by integrating Asia's respective business strengths in addressing the pharmaceutical needs of the Asia-Pacific region. We have the knowledge and know-how of the clinical and regulatory requirements across the Asian region . We manage more than 600 professional sales representatives. We are focused on the marketing and distribution of innovative biotech cancer products in Asian markets with the most cost-effective approaches. We anticipate intense competition in this new market sector, and are working diligently to stay at the forefront of this everchanging competitive environment. BioPro obtained the exclusive rights for the core patented technology - High Throughput Mammalian Protein Expression technology to develop cost effective protein products for bioassay and reagent support and " rapid mammalian production cell development technology and downstream support team for new generations of currently well-known and future protein drugs; We have three protein therapeutics, two antibody therapeutics and two vaccines under development.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

B
BioForce Nanosciences

BioForce Nanosciences develops and commercializes nanotech instruments, consumables, and applications for the life sciences. The Nano eNabler system is a molecular printer that rapidly and precisely delivers liquids to surfaces such as silicon chips in droplets that are ten billion times smaller than a drop of blood. This unique capability offers researchers in industry and academia a practical solution to problems they encounter when developing ultraminiaturized devices and methods, and creates opportunities for further commercialization of nanotechnology. For example, BioForce's technology is being used to create biosensors and to study cell biology at the single cell level. Additional applications include printing proteins to guide neural cell growth, printing signaling proteins to study stem cell differentiation, "inking" of micro-stamps for soft lithography, and bio-functionalization of microfluidic devices.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.